Rhabdomyosarcoma, the most common soft tissue sarcoma in childhood, has challenged and intrigued soft tissue pathologists ever since the original descriptions. Once based on the identification of rhabdomyoblastic cells with elongate eosinophilic cytoplasm, the diagnosis has evolved to include tumors composed only of primitive mesenchymal cells but now relies heavily on immunohistochemical stains for desmin, myogenin, and MyoD. Rhabdomyosarcomas show a variety of histological patterns, giving rise to classifications that have included embryonal, alveolar, botryoid, pleomorphic, spindle cell, and sclerosing subtypes. These have been linked to prognosis and treatment assignment in the past, but that concept has been superseded by the identification of PAX3-FOXO1 or PAX7-FOXO1 fusions. Fusion testing results are more predictive of outcome and have become standard practice in clinical management. However, high risk tumors with alveolar histology or metastatic disease continue to resist oncologic treatment.
BeckwithJB.Benjamin Harrison Landing (1920-2000): reflections and reminiscences.Pediatr Dev Pathol. 2001;
4:205–211.
3.
LandingBHFarberS.Tumors of the Cardiovascular System. Atlas of Tumor Pathology. First Fascicle Series. Washington, DC: Armed Forces Institute of Pathology; 1956.
4.
GBD 2017 Childhood Cancer Collaborators.
The global burden of childhood and adolescent cancer in 2017: an analysis of the Global Burden of Disease Study 2017. Lancet Oncol. 2019;
20:1211–1225.
5.
KahnHJYeger H, Kassim O, et al.
Immunohistochemical and electron microscopic assessment of childhood rhabdomyosarcoma. Increased frequency of diagnosis over routine histologic methods. Cancer. 1983;
51:1897–1903.
6.
KohSJJohnsonWW.Antimyosin and antirhabdomyoblast sera: their use for the diagnosis of childhood rhabdomyosarcoma. Arch Pathol Lab Med. 1980;
104:118–122.
7.
MukaiKRosaiJHallawayBE.Localization of myoglobin in normal and neoplastic human skeletal muscle cells using an immunoperoxidase method. Am J Surg Pathol. 1979;
3:373–376.
8.
EusebiVBondiARosaiJ.Immunohistochemical localization of myoglobin in nonmuscular cells. Am J Surg Pathol. 1984;
8:51–55.
9.
LazaridesE.Intermediate filaments as mechanical integrators of cellular space.Nature. 1980;
283:249–256.
10.
AltmannsbergerMWeberKDrosteROsbornM.Desmin is a specific marker for rhabdomyosarcomas of human and rat origin. Am J Pathol. 1985;
118:85–95.
11.
MiettinenMLehtoVPBadleyRAVirtanenI.Expression of intermediate filaments in soft-tissue sarcomas.Int J Cancer. 1982;
30:541–546.
12.
TruongLD, et al.
The diagnostic utility of desmin. A study of 584 cases and review of the literature.Am J Clin Pathol. 1990;
93:305–314.
13.
WeintraubH, et al.
The myoD gene family: nodal point during specification of the muscle cell lineage.Science. 1991;
251:761–766.
14.
TapscottSJ.The circuitry of a master switch: Myod and the regulation of skeletal muscle gene transcription.Development. 2005;
132:2685–2695.
15.
DiasPParhamDMShapiroDNWebberBLHoughtonPJ.Myogenic regulatory protein (MyoD1) expression in childhood solid tumors: diagnostic utility in rhabdomyosarcoma. Am J Pathol. 1990;
137:1283–1291.
16.
DiasP, et al.
Strong immunostaining for myogenin in rhabdomyosarcoma is significantly associated with tumors of the alveolar subclass. Am J Pathol. 2000;
156:399–408.
17.
MorottiRA, et al.
An immunohistochemical algorithm to facilitate diagnosis and subtyping of rhabdomyosarcoma: the Children’s Oncology Group experience. Am J Surg Pathol. 2006;
30:962–968.
18.
RaneyRBBergeronCParhamD.English Translation of M. Bérard: Tumeur Embryonnaire Du Muscle Strié. [Embryonal tumor of striated muscle]. Lyon Med. 1894;77:52.Fetal Pediatr Pathol. 2019;
38:182–184.
19.
PfannenstielJ.Das traubige Sarcom der Cervix uteri. Archiv für pathologische Anatomie und Physiologie und für klinische Medicin. 1892;
127:305–337.
20.
RaneyRBOberlinOParhamDM.An English Translation of Joseph Luc Riopelle, MD, (Hôtel-Dieu of Montréal), and Jean Paul Thériault (Hôpital Général of Verdun, Québec, Canada): Sur une forme méconnue de sarcome des parties molles: le rhabdomyosarcome alvéolaire (concerning an unrecognized form of sarcoma of the soft tissues: alveolar rhabdomyosarcoma). Annales d’Anatomie Pathologique 1956;1:88–111.Pediatr Dev Pathol. 2012;
15:407–416.
21.
StoutAP.Rhabdomyosarcoma of the skeletal muscles. Ann Surg. 1946;
123:447–472.
22.
HornRCJrEnterlineHT.Rhabdomyosarcoma: a clinicopathological study and classification of 39 cases. Cancer. 1958;
11:181–199.
23.
StoutAPLattesR.Malignant Tumors of Muscle. Atlas of Tumor Pathology, Series 2, Fascicle 1; Tumors of Soft Tissues.
Washington, DC:
Armed Forces Institute of Pathology; 1967:127–133.
24.
Gonzalez-CrussiFBlack-SchafferS.Rhabdomyosarcoma of infancy and childhood. Am J Surg Pathol. 1979;
3:157–171.
25.
NewtonWAJr, et al.
Histopathology of childhood sarcomas, intergroup rhabdomyosarcoma studies I and II: clinicopathologic correlation.J Clin Oncol. 1988;
6:67–75.
26.
CaillaudJM, et al.
Histopathological classification of childhood rhabdomyosarcoma: a report from the International Society of Pediatric Oncology pathology panel.Med Pediatr Oncol. 1989;
17:391–400.
27.
TsokosM, et al.Rhabdomyosarcoma: a new classification scheme related to prognosis. Arch Pathol Lab Med. 1992;
116:847–855.
28.
PalmerNFSachsNFoulkesM.Histology and prognosis in rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Study. Proc SIOP. 1981;
13:113.
29.
PalmerNFSachsNFoulkesM.Histology and prognosis in rhabdomyosarcoma (IRS-I). Proc ASCO. 1982;
1:170.
30.
PalmerNFFoulkesM.Histopathology and prognosis in the second Intergroup Rhabdomyosarcoma Study (IRS II). Proc ASCO. 1983;
2:229.
31.
AsmarL, et al.
Agreement among and within groups of pathologists in the classification of rhabdomyosarcoma and related childhood sarcomas. Report of an international study of four pathology classifications. Cancer. 1994;
74:2579–2588.
32.
NewtonWAJr, et al.Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification–an Intergroup Rhabdomyosarcoma Study. Cancer. 1995;
76:1073–1085.
33.
ChilesMC, et al.
Sclerosing rhabdomyosarcomas in children and adolescents: a clinicopathologic review of 13 cases from the Intergroup Rhabdomyosarcoma Study Group and Children’s Oncology Group.Pediatr Dev Pathol. 2004;
7:583–594.
34.
QualmanSJ, et al.
Intergroup Rhabdomyosarcoma Study: update for pathologists.Pediatr Dev Pathol1998;
1:550–561.
35.
SeidalTMarkJHagmarBAngervallL.Alveolar rhabdomyosarcoma: a cytogenetic and correlated cytological and histological study.Acta Pathol Microbiol Immunol Scand A. 1982;
90:345–354.
36.
BarrFG.Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma.Oncogene. 2001;
20:5736–5746.
37.
GaliliNDavid RJ, Fredericks WJ, et al.
Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma.Nat Genet1993;
5:230–235.
38.
SorensenPHBLynch JC, Qualman SJ, et al.
PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children’s oncology group.J Clin Oncol2002;
20:2672–2679.
39.
RudzinskiERTeot LA, Anderson JR, et al.
Dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. Am J Clin Pathol. 2013;
140:82–90.
40.
DavicioniEFinckenstein FG, Shahbasian, Buckley JD, Triche TJ, Anderson MJ.
Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas.Cancer Res. 2006;
66:6936–6946.
41.
SkapekSXAnderson J, Barr FG, et al.
PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children’s oncology group report. Pediatr Blood Cancer. 2013;
60:1411–1417.
42.
MissiagliaEWilliamson D, Chisholm J, et al.
PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.J Clin Oncol. 2012;
30:1670–1677.
43.
HibbittsEChi YY, Hawkins DS, et al.
Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: a report from the Children’s Oncology Group.Cancer Med2019;
8:6437–6448.
44.
PrattCBHustuHOFlemingIDPinkelD,
Coordinated treatment of childhood rhabdomyosarcoma with surgery, radiotherapy, and combination chemotherapy. Cancer Res. 1972;
32:606–610.
45.
MaurerHMBeltangady M, Gehan EA, et al.
The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer. 1988;
61:209–220.
46.
MaurerHMGehan EA, Beltangady M, et al.
The Intergroup Rhabdomyosarcoma Study-II. Cancer. 1993;
71:1904–1922.
47.
CristWGehan EA, Ragab AH, et al.
The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol. 1995;
13:610–630.
48.
CristWMAnderson JR, Meza JL, et al.
Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease.J Clin Oncol. 2001;
19:3091–3102.
49.
BrenemanJCLyden E, Pappo AS, et al.
Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma–a report from the Intergroup Rhabdomyosarcoma Study IV.J Clin Oncol. 2003;
21:78–84.
50.
WeigelBJLyden E, Anderson JR, et al.
Intensive multiagent therapy, including dose-compressed cycles of ifosfamide/etoposide and vincristine/doxorubicin/cyclophosphamide, irinotecan, and radiation, in patients with high-risk rhabdomyosarcoma: a report from the Children’s Oncology Group. J Clin Oncol. 2016;
34:117–122.
51.
PappoASLyden E, Breitfeld, et al.
Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children’s Oncology Group.J Clin Oncol. 2007;
25:362–369.
52.
HawkinsDSChi YY, Anderson JR, et al.
Addition of vincristine and irinotecan to vincristine, dactinomycin, and cyclophosphamide does not improve outcome for intermediate-risk rhabdomyosarcoma: a report from the Children’s Oncology Group. J Clin Oncol. 2018;
36:2770–2777.
53.
MascarenhasLLyden ER, Breitfield PP, et al.
Risk-based treatment for patients with first relapse or progression of rhabdomyosarcoma: a report from the Children’s Oncology Group.Cancer. 2019;
125:2602–2609.
